STS/SCA/AmSECT Clinical Practice Guidelines

Anticoagulation during Cardiopulmonary Bypass

Linda Shore-Lesserson, Robert A. Baker, Victor Ferraris, Philip E. Greilich, David Fitzgerald, Philip Roman, John Hammon

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Despite more than a half century of "safe" cardiopulmonary bypass (CPB), the evidence base surrounding the conduct of anticoagulation for CPB has not been organized into a succinct guideline. For this and other reasons, there is enormous practice variability relating to the use and dosing of heparin, monitoring heparin anticoagulation, reversal of anticoagulation, and the use of alternative anticoagulants. To address this and other gaps, the Society of Thoracic Surgeons (STS), the Society of Cardiovascular Anesthesiologists (SCA), and the American Society of Extracorporeal Technology (AmSECT) developed an Evidence Based Workgroup. This was a group of interdisciplinary professionals gathered together to summarize the evidence and create practice recommendations for various aspects of CPB. To date, anticoagulation practices in CPB have not been standardized in accordance with the evidence base. This clinical practice guideline was written with the intent to fill the evidence gap and to establish best practices in anticoagulation for CPB using the available evidence. To identify relevant evidence a systematic review was outlined and literature searches were conducted in PubMed® using standardized MeSH terms from the National Library of Medicine list of search terms. Search dates were inclusive of January 2000 to December 2015. The search yielded 833 abstracts which were reviewed by two independent reviewers. Once accepted into the full manuscript review stage, two members of the writing group evaluated each of 286 full papers for inclusion eligibility into the guideline document. Ninety-six manuscripts were included in the final review. In addition, 17 manuscripts published prior to 2000 were included to provide method, context, or additional supporting evidence for the recommendations as these papers were considered sentinel publications. Members of the writing group wrote and developed recommendations based on review of the articles obtained and achieved more than two thirds agreement on each recommendation. The quality of information for a given recommendation allowed assessment of the level of evidence as recommended by the AHA/ACCF Task Force on Practice Guidelines. Recommendations were written in the three following areas 1) Heparin dosing and monitoring for initiation and maintenance of CPB, 2) Heparin contraindications and heparin alternatives, 3) Reversal of anticoagulation during cardiac operations. It is hoped that this guideline will serve as a resource and will stimulate investigators to conduct more research and expand upon the evidence base on the topic of anticoagulation for CPB.

Original languageEnglish (US)
Pages (from-to)5-18
Number of pages14
JournalThe journal of extra-corporeal technology
Volume50
Issue number1
StatePublished - Mar 1 2018

Fingerprint

Cardiopulmonary Bypass
Practice Guidelines
Thorax
Technology
Heparin
Manuscripts
Guidelines
National Library of Medicine (U.S.)
Advisory Committees
Surgeons
Anesthesiologists
PubMed
Anticoagulants
Publications
Maintenance
Research Personnel
Research

Keywords

  • anticoagulation reversal
  • bivalirudin
  • cardiopulmonary bypass
  • heparin
  • heparin alternatives
  • protamine

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Professions (miscellaneous)
  • Cardiology and Cardiovascular Medicine

Cite this

Shore-Lesserson, L., Baker, R. A., Ferraris, V., Greilich, P. E., Fitzgerald, D., Roman, P., & Hammon, J. (2018). STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass. The journal of extra-corporeal technology, 50(1), 5-18.

STS/SCA/AmSECT Clinical Practice Guidelines : Anticoagulation during Cardiopulmonary Bypass. / Shore-Lesserson, Linda; Baker, Robert A.; Ferraris, Victor; Greilich, Philip E.; Fitzgerald, David; Roman, Philip; Hammon, John.

In: The journal of extra-corporeal technology, Vol. 50, No. 1, 01.03.2018, p. 5-18.

Research output: Contribution to journalArticle

Shore-Lesserson, L, Baker, RA, Ferraris, V, Greilich, PE, Fitzgerald, D, Roman, P & Hammon, J 2018, 'STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass', The journal of extra-corporeal technology, vol. 50, no. 1, pp. 5-18.
Shore-Lesserson L, Baker RA, Ferraris V, Greilich PE, Fitzgerald D, Roman P et al. STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass. The journal of extra-corporeal technology. 2018 Mar 1;50(1):5-18.
Shore-Lesserson, Linda ; Baker, Robert A. ; Ferraris, Victor ; Greilich, Philip E. ; Fitzgerald, David ; Roman, Philip ; Hammon, John. / STS/SCA/AmSECT Clinical Practice Guidelines : Anticoagulation during Cardiopulmonary Bypass. In: The journal of extra-corporeal technology. 2018 ; Vol. 50, No. 1. pp. 5-18.
@article{aee642cf3a254eea8ab74936ee3df7ea,
title = "STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass",
abstract = "Despite more than a half century of {"}safe{"} cardiopulmonary bypass (CPB), the evidence base surrounding the conduct of anticoagulation for CPB has not been organized into a succinct guideline. For this and other reasons, there is enormous practice variability relating to the use and dosing of heparin, monitoring heparin anticoagulation, reversal of anticoagulation, and the use of alternative anticoagulants. To address this and other gaps, the Society of Thoracic Surgeons (STS), the Society of Cardiovascular Anesthesiologists (SCA), and the American Society of Extracorporeal Technology (AmSECT) developed an Evidence Based Workgroup. This was a group of interdisciplinary professionals gathered together to summarize the evidence and create practice recommendations for various aspects of CPB. To date, anticoagulation practices in CPB have not been standardized in accordance with the evidence base. This clinical practice guideline was written with the intent to fill the evidence gap and to establish best practices in anticoagulation for CPB using the available evidence. To identify relevant evidence a systematic review was outlined and literature searches were conducted in PubMed{\circledR} using standardized MeSH terms from the National Library of Medicine list of search terms. Search dates were inclusive of January 2000 to December 2015. The search yielded 833 abstracts which were reviewed by two independent reviewers. Once accepted into the full manuscript review stage, two members of the writing group evaluated each of 286 full papers for inclusion eligibility into the guideline document. Ninety-six manuscripts were included in the final review. In addition, 17 manuscripts published prior to 2000 were included to provide method, context, or additional supporting evidence for the recommendations as these papers were considered sentinel publications. Members of the writing group wrote and developed recommendations based on review of the articles obtained and achieved more than two thirds agreement on each recommendation. The quality of information for a given recommendation allowed assessment of the level of evidence as recommended by the AHA/ACCF Task Force on Practice Guidelines. Recommendations were written in the three following areas 1) Heparin dosing and monitoring for initiation and maintenance of CPB, 2) Heparin contraindications and heparin alternatives, 3) Reversal of anticoagulation during cardiac operations. It is hoped that this guideline will serve as a resource and will stimulate investigators to conduct more research and expand upon the evidence base on the topic of anticoagulation for CPB.",
keywords = "anticoagulation reversal, bivalirudin, cardiopulmonary bypass, heparin, heparin alternatives, protamine",
author = "Linda Shore-Lesserson and Baker, {Robert A.} and Victor Ferraris and Greilich, {Philip E.} and David Fitzgerald and Philip Roman and John Hammon",
year = "2018",
month = "3",
day = "1",
language = "English (US)",
volume = "50",
pages = "5--18",
journal = "Journal of Extra-Corporeal Technology",
issn = "0022-1058",
publisher = "American Society of Extra-Corporeal Technology",
number = "1",

}

TY - JOUR

T1 - STS/SCA/AmSECT Clinical Practice Guidelines

T2 - Anticoagulation during Cardiopulmonary Bypass

AU - Shore-Lesserson, Linda

AU - Baker, Robert A.

AU - Ferraris, Victor

AU - Greilich, Philip E.

AU - Fitzgerald, David

AU - Roman, Philip

AU - Hammon, John

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Despite more than a half century of "safe" cardiopulmonary bypass (CPB), the evidence base surrounding the conduct of anticoagulation for CPB has not been organized into a succinct guideline. For this and other reasons, there is enormous practice variability relating to the use and dosing of heparin, monitoring heparin anticoagulation, reversal of anticoagulation, and the use of alternative anticoagulants. To address this and other gaps, the Society of Thoracic Surgeons (STS), the Society of Cardiovascular Anesthesiologists (SCA), and the American Society of Extracorporeal Technology (AmSECT) developed an Evidence Based Workgroup. This was a group of interdisciplinary professionals gathered together to summarize the evidence and create practice recommendations for various aspects of CPB. To date, anticoagulation practices in CPB have not been standardized in accordance with the evidence base. This clinical practice guideline was written with the intent to fill the evidence gap and to establish best practices in anticoagulation for CPB using the available evidence. To identify relevant evidence a systematic review was outlined and literature searches were conducted in PubMed® using standardized MeSH terms from the National Library of Medicine list of search terms. Search dates were inclusive of January 2000 to December 2015. The search yielded 833 abstracts which were reviewed by two independent reviewers. Once accepted into the full manuscript review stage, two members of the writing group evaluated each of 286 full papers for inclusion eligibility into the guideline document. Ninety-six manuscripts were included in the final review. In addition, 17 manuscripts published prior to 2000 were included to provide method, context, or additional supporting evidence for the recommendations as these papers were considered sentinel publications. Members of the writing group wrote and developed recommendations based on review of the articles obtained and achieved more than two thirds agreement on each recommendation. The quality of information for a given recommendation allowed assessment of the level of evidence as recommended by the AHA/ACCF Task Force on Practice Guidelines. Recommendations were written in the three following areas 1) Heparin dosing and monitoring for initiation and maintenance of CPB, 2) Heparin contraindications and heparin alternatives, 3) Reversal of anticoagulation during cardiac operations. It is hoped that this guideline will serve as a resource and will stimulate investigators to conduct more research and expand upon the evidence base on the topic of anticoagulation for CPB.

AB - Despite more than a half century of "safe" cardiopulmonary bypass (CPB), the evidence base surrounding the conduct of anticoagulation for CPB has not been organized into a succinct guideline. For this and other reasons, there is enormous practice variability relating to the use and dosing of heparin, monitoring heparin anticoagulation, reversal of anticoagulation, and the use of alternative anticoagulants. To address this and other gaps, the Society of Thoracic Surgeons (STS), the Society of Cardiovascular Anesthesiologists (SCA), and the American Society of Extracorporeal Technology (AmSECT) developed an Evidence Based Workgroup. This was a group of interdisciplinary professionals gathered together to summarize the evidence and create practice recommendations for various aspects of CPB. To date, anticoagulation practices in CPB have not been standardized in accordance with the evidence base. This clinical practice guideline was written with the intent to fill the evidence gap and to establish best practices in anticoagulation for CPB using the available evidence. To identify relevant evidence a systematic review was outlined and literature searches were conducted in PubMed® using standardized MeSH terms from the National Library of Medicine list of search terms. Search dates were inclusive of January 2000 to December 2015. The search yielded 833 abstracts which were reviewed by two independent reviewers. Once accepted into the full manuscript review stage, two members of the writing group evaluated each of 286 full papers for inclusion eligibility into the guideline document. Ninety-six manuscripts were included in the final review. In addition, 17 manuscripts published prior to 2000 were included to provide method, context, or additional supporting evidence for the recommendations as these papers were considered sentinel publications. Members of the writing group wrote and developed recommendations based on review of the articles obtained and achieved more than two thirds agreement on each recommendation. The quality of information for a given recommendation allowed assessment of the level of evidence as recommended by the AHA/ACCF Task Force on Practice Guidelines. Recommendations were written in the three following areas 1) Heparin dosing and monitoring for initiation and maintenance of CPB, 2) Heparin contraindications and heparin alternatives, 3) Reversal of anticoagulation during cardiac operations. It is hoped that this guideline will serve as a resource and will stimulate investigators to conduct more research and expand upon the evidence base on the topic of anticoagulation for CPB.

KW - anticoagulation reversal

KW - bivalirudin

KW - cardiopulmonary bypass

KW - heparin

KW - heparin alternatives

KW - protamine

UR - http://www.scopus.com/inward/record.url?scp=85049235305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049235305&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 5

EP - 18

JO - Journal of Extra-Corporeal Technology

JF - Journal of Extra-Corporeal Technology

SN - 0022-1058

IS - 1

ER -